Clinical disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change medication without clinical supervision.

Key Points

  • In phase 3, once-weekly icodec provided better glycaemic control than once-daily insulin glargine U100 in insulin-naive type 2 diabetes
  • Awiqli (insulin icodec-abae) was FDA approved in March 2026 for adults with type 2 diabetes
  • Weekly insulin changes treatment cadence and potentially lowers the psychological barrier to intensification
  • Weekly dosing also raises the stakes of getting a dose wrong — correct dose selection and patient education matter more
  • Treatment burden is not a cosmetic issue — a therapy that reduces friction without sacrificing control can change when diabetes is intensified

Insulin icodec matters because it tackles one of the least glamorous but most consequential problems in diabetes care: treatment burden. In a phase 3 trial in insulin-naive adults with type 2 diabetes, once-weekly icodec provided better glycaemic control than once-daily insulin glargine U100. [1] In March 2026, the FDA approved insulin icodec-abae as Awiqli for adults with type 2 diabetes. [2,3]

What the trial showed

Weekly insulin is not just a convenience tweak. It changes the cadence of treatment, the psychological burden of daily injection, and potentially the threshold at which both clinicians and patients are willing to intensify therapy.

The evidence says it can be taken seriously. [1,3] The question is not merely whether people like the idea of weekly insulin — it is whether weekly insulin can deliver strong control without creating an unacceptable safety or usability problem.

What most articles miss

The tendency is to flatten "weekly" into "obviously better." Weekly dosing may reduce daily friction, but it also raises the stakes of getting a dose wrong, forgetting a dose or misunderstanding the titration process. The approved Awiqli label is explicit about careful dose selection and pen-specific handling because the concentration and weekly schedule differ from familiar daily insulin routines. [3]

Bottom line

Once-weekly basal insulin matters because treatment burden is not a cosmetic issue. A therapy that reduces friction without sacrificing control can change when and how diabetes is intensified. The hard part is safe implementation. [1,3]

FAQ

What is Awiqli?
Awiqli is the FDA-approved brand name for insulin icodec-abae, a once-weekly basal insulin for adults with type 2 diabetes. [2,3]
What did the main trial show?
In insulin-naive adults with type 2 diabetes, once-weekly icodec achieved better glycaemic control than once-daily glargine U100 in a phase 3 trial. [1]
Does weekly insulin mean fewer problems?
Potentially fewer daily hassles, yes. But weekly dosing also makes correct dose selection and patient education more important. [3]
Why is this relevant to a metabolic evidence hub?
Because diabetes-treatment burden is part of metabolic care, and changes in delivery architecture can have major real-world effects.
Is Awiqli right for every patient who uses basal insulin?
No. Suitability depends on safety, self-management capacity, glucose targets and clinical context. [3]

References

  1. Rosenstock J, et al. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med. 2023;389:297-308. nejm.org
  2. Novel Drug Approvals for 2026. FDA. 2026.
  3. Awiqli (insulin icodec-abae) prescribing information. FDA. 2026. accessdata.fda.gov